PMID- 25227424
OWN - NLM
STAT- MEDLINE
DCOM- 20151019
LR  - 20211021
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 9
DP  - 2014 Sep 17
TI  - Correlation of EGFR expression, gene copy number and clinicopathological status 
      in NSCLC.
PG  - 165
LID - 10.1186/s13000-014-0165-0 [doi]
LID - 165
AB  - BACKGROUND: Epidermal Growth Factor Receptor (EGFR) targeting therapies are 
      currently of great relevance for the treatment of lung cancer. For this reason, 
      in addition to mutational analysis immunohistochemistry (IHC) of EGFR in lung 
      cancer has been discussed for the decision making of according therapeutic 
      strategies. The aim of this study was to obtain standardization of 
      EGFR-expression methods for the selection of patients who might benefit of EGFR 
      targeting therapies. METHODS: As a starting point of a broad investigation, aimed 
      at elucidating the expression of EGFR on different biological levels, four EGFR 
      specific antibodies were analyzed concerning potential differences in expression 
      levels by Immunohistochemistry (IHC) and correlated with fluorescence in situ 
      hybridization (FISH) analysis and clinicopathological data. 206 tumor tissues 
      were analyzed in a tissue microarray format employing immunohistochemistry with 
      four different antibodies including Dako PharmDx kit (clone 2-18C9), clone 31G7, 
      clone 2.1E1 and clone SP84 using three different scoring methods. Protein 
      expression was compared to FISH utilizing two different probes. RESULTS: EGFR 
      protein expression determined by IHC with Dako PharmDx kit, clone 31G7 and clone 
      2.1E1 (p </= 0.05) correlated significantly with both FISH probes independently of 
      the three scoring methods; best correlation is shown for 31G7 using the scoring 
      method that defined EGFR positivity when >/= 10% of the tumor cells show membranous 
      staining of moderate and severe intensity (p=0.001). CONCLUSION: Overall, our 
      data show differences in EGFR expression determined by IHC, due to the applied 
      antibody. Highest concordance with FISH is shown for antibody clone 31G7, 
      evaluated with score B (p=0.001). On this account, this antibody clone might by 
      utilized for standard evaluation of EGFR expression by IHC. VIRTUAL SLIDES: The 
      virtual slide(s) for this article can be found here: 
      http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_165.
FAU - Gaber, Rania
AU  - Gaber R
FAU - Watermann, Iris
AU  - Watermann I
FAU - Kugler, Christian
AU  - Kugler C
FAU - Reinmuth, Nils
AU  - Reinmuth N
FAU - Huber, Rudolf M
AU  - Huber RM
FAU - Schnabel, Philipp A
AU  - Schnabel PA
FAU - Vollmer, Ekkehard
AU  - Vollmer E
FAU - Reck, Martin
AU  - Reck M
FAU - Goldmann, Torsten
AU  - Goldmann T
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140917
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (Antibodies)
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Antibodies/immunology
MH  - Carcinoid Tumor/diagnosis/genetics/pathology
MH  - Carcinoma, Adenosquamous/diagnosis/genetics/pathology
MH  - Carcinoma, Large Cell/diagnosis/genetics/pathology
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/genetics/*pathology
MH  - DNA, Neoplasm/genetics
MH  - Diagnosis, Differential
MH  - ErbB Receptors/*genetics/immunology/metabolism
MH  - Female
MH  - Gene Dosage/*genetics
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Immunohistochemistry/*methods/standards
MH  - In Situ Hybridization, Fluorescence/*methods/standards
MH  - Lung Neoplasms/diagnosis/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Reproducibility of Results
PMC - PMC4176848
EDAT- 2014/09/18 06:00
MHDA- 2015/10/20 06:00
PMCR- 2014/09/17
CRDT- 2014/09/18 06:00
PHST- 2014/07/07 00:00 [received]
PHST- 2014/08/16 00:00 [accepted]
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2015/10/20 06:00 [medline]
PHST- 2014/09/17 00:00 [pmc-release]
AID - s13000-014-0165-0 [pii]
AID - 165 [pii]
AID - 10.1186/s13000-014-0165-0 [doi]
PST - epublish
SO  - Diagn Pathol. 2014 Sep 17;9:165. doi: 10.1186/s13000-014-0165-0.